SAN FRANCISCO, Mar 11: Gilead Sciences Inc’s <GILD.O> angina drug Ranexa reduced incidents of chest pain in patients with diabetes, and the effect appeared to be more pronounced in those with poor blood sugar control, according to data from a clinical trial. Ranexa, known chemically as ranolazine, is already approved to treat angina – a type of chest pain associated with heart disease. This was the first trial to test it specifically in diabetics, who tend to have more complications and can be more difficult to treat that other heart patients. (agencies)
Trending Now
E-Paper
Follow our WhatsApp channel